8-K Announcements
6Material company update
Mar 19, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Feb 27, 2026·SEC
Larimar Therapeutics, Inc.(LRMR)Earnings, Financials & Key Ratios
LRMR•NASDAQ
$4.15
$355M mkt cap·Price updated May 6, 2026
AboutLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.Show more
- Revenue$0
- EBITDA-$172M-90.1%
- Net Income-$166M-105.5%
- EPS (Diluted)-2.27-72.0%
- ROE-132.59%-108.5%
- ROIC-184.22%-176.0%
- Debt/Equity0.05+74.9%
LRMR Key Insights
Larimar Therapeutics, Inc. (LRMR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 31.4% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 19.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LRMR Price & Volume
Larimar Therapeutics, Inc. (LRMR) stock price & volume — 10-year historical chart
Loading chart...
LRMR Growth Metrics
Larimar Therapeutics, Inc. (LRMR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-105.54%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-70%
Return on Capital
10 Years-62.7%
5 Years-69.05%
3 Years-81.63%
Last Year-134.28%
LRMR Recent Earnings
Larimar Therapeutics, Inc. (LRMR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
Mar 19, 2026EPS
$0.73
Est $0.44
-65.9%
Revenue
—
Q4 2025
Nov 5, 2025EPS
$0.61
Est $0.39
-56.4%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.41
Est $0.47
+12.8%
Revenue
—
Q2 2025
Apr 30, 2025EPS
$0.46
Est $0.42
-9.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 19, 2026 | $0.73vs $0.44-65.9% | — |
| Q4 2025 | Nov 5, 2025 | $0.61vs $0.39-56.4% | — |
| Q3 2025 | Aug 14, 2025 | $0.41vs $0.47+12.8% | — |
| Q2 2025 | Apr 30, 2025 | $0.46vs $0.42-9.5% | — |
Based on last 12 quarters of dataView full earnings history →
LRMR Peer Comparison
Larimar Therapeutics, Inc. (LRMR) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 AVNS | 1.15B | 24.72 | -16.93 | 1.95% | -9.69% | -8.91% | 0.17 | |
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 |
Compare LRMR vs Peers
Larimar Therapeutics, Inc. (LRMR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LRMR Income Statement
Larimar Therapeutics, Inc. (LRMR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 188K | 261K | 78K | 155K | 0 | 0 | 0 | 0 | 350K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -188K▲ 0% | -261K▼ 38.8% | -78K▲ 70.1% | -155K▼ 98.7% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -350K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 11.32% | -38.83% | 70.11% | -98.72% | 100% | - | - | - | - |
| Operating Expenses | 53.69M | 62.46M | 23.21M | 42.65M | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 11.95M | 12.93M | 2.42M | 11.4M | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 41.74M | 49.53M | 20.79M | 31.25M | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 82K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -53.88M▲ 0% | -62.72M▼ 16.4% | -23.21M▲ 63.0% | -42.8M▼ 84.4% | -50.47M▼ 17.9% | -36.53M▲ 27.6% | -41.76M▼ 14.3% | -90.89M▼ 117.7% | -172.5M▼ 89.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 5.68% | -16.42% | 62.99% | -84.39% | -17.9% | 27.62% | -14.32% | -117.66% | -89.79% |
| EBITDA | -53.69M | -62.46M | -23.14M | -42.65M | -50.14M | -36.21M | -41.45M | -90.57M | -172.15M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 5.66% | -16.34% | 62.96% | -84.34% | -17.56% | 27.78% | -14.47% | -118.52% | -90.07% |
| D&A (Non-Cash Add-back) | 188K | 261K | 78K | 155K | 326K | 318K | 311K | 318K | 350K |
| EBIT | -52.76M | -61.07M | -23.21M | -42.8M | -50.47M | -36.53M | -41.76M | -90.89M | -172.5M |
| Net Interest Income | 25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 996K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 971K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 947K | -246K | 82K | 322K | -171K | 1.17M | 4.81M | 10.29M | 6.82M |
| Pretax Income | -52.93M▲ 0% | -62.97M▼ 19.0% | -23.13M▲ 63.3% | -42.48M▼ 83.7% | -50.64M▼ 19.2% | -35.35M▲ 30.2% | -36.95M▼ 4.5% | -80.6M▼ 118.1% | -165.67M▼ 105.5% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | -900K | -1.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.7% | 2.54% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -52.03M▲ 0% | -61.37M▼ 18.0% | -23.13M▲ 62.3% | -42.33M▼ 83.0% | -50.64M▼ 19.6% | -35.35M▲ 30.2% | -36.95M▼ 4.5% | -80.6M▼ 118.1% | -165.67M▼ 105.5% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 10.11% | -17.95% | 62.31% | -82.98% | -19.63% | 30.18% | -4.51% | -118.15% | -105.54% |
| Net Income (Continuing) | -52.03M | -61.37M | -23.13M | -42.48M | -50.64M | -35.35M | -36.95M | -80.6M | -165.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -22.76▲ 0% | -22.85▼ 0.4% | -2.51▲ 89.0% | -3.56▼ 41.8% | -2.93▲ 17.7% | -1.33▲ 54.6% | -0.84▲ 36.8% | -1.32▼ 57.1% | -2.27▼ 72.0% |
| EPS Growth % | 10.53% | -0.4% | 89.02% | -41.83% | 17.7% | 54.61% | 36.84% | -57.14% | -71.97% |
| EPS (Basic) | -22.76 | -22.85 | -2.51 | -3.56 | -2.93 | -1.33 | -0.84 | -1.32 | -2.27 |
| Diluted Shares Outstanding | 2.29M | 2.69M | 9.21M | 11.88M | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Basic Shares Outstanding | 2.29M | 2.69M | 9.21M | 11.88M | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
LRMR Balance Sheet
Larimar Therapeutics, Inc. (LRMR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 104.92M | 121.33M | 4.75M | 97.95M | 72.2M | 120.74M | 90.17M | 195.3M | 142.02M |
| Cash & Short-Term Investments | 102.05M | 118.07M | 1.01M | 92.64M | 70.1M | 118.43M | 86.79M | 183.45M | 136.85M |
| Cash Only | 40.78M | 49.33M | 1.01M | 68.15M | 70.1M | 26.82M | 26.75M | 33.22M | 85.41M |
| Short-Term Investments | 61.27M | 68.73M | 0 | 24.49M | 0 | 91.6M | 60.04M | 150.24M | 51.44M |
| Accounts Receivable | 946K | 1.54M | 158K | 32K | 208K | 0 | 0 | 1.05M | 747K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.93M | 1.73M | 448K | 251K | 279K | 238K | 709K | 10.8M | 4.42M |
| Total Non-Current Assets | 585K | 432K | 451K | 6.73M | 6.46M | 5.67M | 5.76M | 4.92M | 3.82M |
| Property, Plant & Equipment | 528K | 375K | 361K | 4.98M | 4.46M | 3.69M | 3.76M | 3.72M | 2.69M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1.34M | 0 | 0 |
| Other Non-Current Assets | 57K | 57K | 90K | 1.76M | 2.01M | 1.98M | 659K | 1.2M | 1.13M |
| Total Assets | 105.51M▲ 0% | 121.76M▲ 15.4% | 5.2M▼ 95.7% | 104.69M▲ 1912.8% | 78.67M▼ 24.9% | 126.41M▲ 60.7% | 95.94M▼ 24.1% | 200.22M▲ 108.7% | 145.84M▼ 27.2% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -19.84% | 15.4% | -95.73% | 1912.81% | -24.85% | 60.68% | -24.11% | 108.71% | -27.16% |
| Total Current Liabilities | 7.29M | 13.31M | 5.89M | 8.99M | 8.85M | 10.71M | 9.51M | 24.36M | 64.8M |
| Accounts Payable | 0 | 909K | 3.54M | 2.63M | 1.66M | 1.69M | 1.28M | 2.42M | 5.22M |
| Days Payables Outstanding | - | 1.27K | 16.56K | 6.2K | - | - | - | - | 5.44K |
| Short-Term Debt | 0 | 5.46M | 0 | 0 | 0 | 0 | 0 | 0 | 1.1M |
| Deferred Revenue (Current) | 0 | -5.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.27M | 4.65M | 0 | 0 | 0 | 0 | 0 | 0 | 58.47M |
| Current Ratio | 14.39x | 9.12x | 0.81x | 10.89x | 8.16x | 11.28x | 9.49x | 8.02x | 2.19x |
| Quick Ratio | 14.39x | 9.12x | 0.81x | 10.89x | 8.16x | 11.28x | 9.49x | 8.02x | 2.19x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 20M | 15.19M | 0 | 6M | 5.41M | 4.8M | 4.71M | 4.06M | 2.96M |
| Long-Term Debt | 20M | 15.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 6M | 5.41M | 4.8M | 4.71M | 4.06M | 2.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 27.29M | 28.49M | 5.89M | 14.99M | 14.25M | 15.5M | 14.21M | 28.41M | 67.76M |
| Total Debt | 20M | 20.64M | 97K | 6.52M | 6M | 5.41M | 5.55M | 5.12M | 4.07M |
| Net Debt | -20.78M | -28.69M | -912K | -61.63M | -64.09M | -21.42M | -21.2M | -28.1M | -81.34M |
| Debt / Equity | 0.26x | 0.22x | - | 0.07x | 0.09x | 0.05x | 0.07x | 0.03x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -54.34x | - | - | - | - | - | - | - | - |
| Total Equity | 78.22M▲ 0% | 93.27M▲ 19.2% | -694K▼ 100.7% | 89.69M▲ 13023.9% | 64.41M▼ 28.2% | 110.9M▲ 72.2% | 81.72M▼ 26.3% | 171.81M▲ 110.2% | 78.08M▼ 54.6% |
| Equity Growth % | -35.74% | 19.25% | -100.74% | 13023.92% | -28.18% | 72.17% | -26.31% | 110.24% | -54.55% |
| Book Value per Share | 34.21 | 34.73 | -0.08 | 7.55 | 3.75 | 4.31 | 1.86 | 2.80 | 1.07 |
| Total Shareholders' Equity | 78.22M | 93.27M | -694K | 89.69M | 64.41M | 110.9M | 81.72M | 171.81M | 78.08M |
| Common Stock | 27K | 37K | 6K | 15K | 18K | 43K | 43K | 64K | 83K |
| Retained Earnings | -289.58M | -350.94M | -23.13M | -65.61M | -116.25M | -151.6M | -188.55M | -269.16M | -434.83M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -58K | -33K | 0 | 1K | 0 | -31K | 81K | 148K | 54K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LRMR Cash Flow Statement
Larimar Therapeutics, Inc. (LRMR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -43.78M | -51.49M | -22.7M | -42.2M | -42.1M | -27.57M | -33.46M | -70.76M | -113.2M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 15.76% | -17.59% | 55.91% | -85.91% | 0.22% | 34.52% | -21.36% | -111.48% | -59.98% |
| Net Income | -52.03M | -61.37M | -23.13M | -42.48M | -50.64M | -35.35M | -36.95M | -80.6M | -165.67M |
| Depreciation & Amortization | 188K | 261K | 78K | 155K | 326K | 318K | 311K | 318K | -1.35M |
| Stock-Based Compensation | 0 | 173K | 129K | 2.16M | 5.47M | 6.62M | 0 | 8.8M | 7M |
| Deferred Taxes | 0 | -9.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 9.08M | 9.78M | 0 | 10K | -15K | -820K | 5.69M | -5.45M | -281K |
| Working Capital Changes | -99K | 593K | 226K | -2.04M | 2.75M | 1.67M | -2.51M | 6.17M | 47.1M |
| Change in Receivables | -553K | -666K | 1.29M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -448K | 432K | 2.63M | -3.29M | -974K | 26K | -403K | 1.14M | 2.79M |
| Cash from Investing | 35.65M | -6.87M | -83K | 17.09M | 24.17M | -90.96M | 33.35M | -85.39M | 100.31M |
| Capital Expenditures | -55K | -108K | -83K | -62K | -333K | -100K | -164K | -515K | -91K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 6.76M | 0 | -1.3M | -24.5K | 90.86K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 35.7M | -6.76M | 0 | 41.93M | 24.5K | -90.86K | 0 | 0 | 0 |
| Cash from Financing | 16.56M | 66.91M | 19.39M | 93.59M | 19.89M | 75.26M | 30K | 161.88M | 65.09M |
| Debt Issued (Net) | 16.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 195K | 66.91M | 19.39M | 75.59M | 19.89M | 75.26M | 30K | 161.81M | 65.09M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 195K | 67.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 18M | 0 | 0 | 0 | 77K | 0 |
| Net Change in Cash | 8.43M▲ 0% | 8.55M▲ 1.5% | -48.32M▼ 664.9% | 68.48M▲ 241.7% | 1.95M▼ 97.2% | -43.27M▼ 2320.2% | -76K▲ 99.8% | 5.74M▲ 7647.4% | 52.19M▲ 809.9% |
| Free Cash Flow | -43.84M▲ 0% | -51.59M▼ 17.7% | -22.78M▲ 55.8% | -42.26M▼ 85.5% | -42.44M▼ 0.4% | -27.67M▲ 34.8% | -33.62M▼ 21.5% | -71.28M▼ 112.0% | -113.29M▼ 59.0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 16.71% | -17.69% | 55.84% | -85.5% | -0.42% | 34.8% | -21.52% | -111.98% | -58.95% |
| FCF per Share | -19.18 | -19.21 | -2.47 | -3.56 | -2.47 | -1.07 | -0.77 | -1.16 | -1.55 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.84x | 0.98x | 1.00x | 0.83x | 0.78x | 0.91x | 0.88x | 0.68x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LRMR Key Ratios
Larimar Therapeutics, Inc. (LRMR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.8% | -52.04% | -71.57% | -49.97% | -95.12% | -65.72% | -40.33% | -38.36% | -63.58% | -132.59% |
| Return on Invested Capital (ROIC) | -36.79% | -53.73% | -77.1% | -55.29% | -242.7% | -266.74% | -61.01% | -41.76% | -66.76% | -184.22% |
| Debt / Equity | 0.03x | 0.26x | 0.22x | - | 0.07x | 0.09x | 0.05x | 0.07x | 0.03x | 0.05x |
| Interest Coverage | -166.14x | -54.34x | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.90x | 0.84x | 0.84x | 0.98x | 1.00x | 0.83x | 0.78x | 0.91x | 0.88x | 0.68x |
LRMR SEC Filings & Documents
Larimar Therapeutics, Inc. (LRMR) SEC filings — annual & quarterly reports (10-K, 10-Q)
LRMR Frequently Asked Questions
Larimar Therapeutics, Inc. (LRMR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Larimar Therapeutics, Inc. (LRMR) grew revenue by 0.0% over the past year. Growth has been modest.
Larimar Therapeutics, Inc. (LRMR) reported a net loss of $165.7M for fiscal year 2025.
Dividend & Returns
Larimar Therapeutics, Inc. (LRMR) has a return on equity (ROE) of -132.6%. Negative ROE indicates the company is unprofitable.
Larimar Therapeutics, Inc. (LRMR) had negative free cash flow of $113.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More LRMR
Larimar Therapeutics, Inc. (LRMR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates